Fabry Disease Market Set for Significant Growth Through 2034 | DelveInsight
The Fabry disease market is on an upward trajectory, driven by increasing awareness, improved diagnostic capabilities, and a rising number of identified cases. Although enzyme replacement therapies (ERTs) and GALAFOLD currently lead the treatment space, a new generation of gene therapies and novel therapeutic agents holds considerable promise for the future. Despite this optimism, the market continues to face notable hurdles, including gaps in pediatric treatment and questions about the long-term effectiveness of available options. Continued investment in innovation and broader patient access will be essential drivers of sustained market growth.
DelveInsight's latest Fabry Disease Market Insights report delivers an in-depth examination of the current treatment environment, including drugs in development, market share held by individual therapies, and projected market sizing across the 2020–2034 study period. The analysis covers seven major markets (7MM): the United States, the EU4 nations (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
According to DelveInsight's findings, the combined Fabry disease market across the 7MM reached an estimated value of approximately USD 1.7 billion in 2024 and is projected to experience positive growth by 2034. The United States accounted for the largest share - roughly 52% of the total 7MM market - surpassing the EU4 countries, the UK, and Japan. Across all seven markets, approximately 17,000 diagnosed prevalent cases of Fabry disease were recorded in 2024. Several major pharmaceutical players are actively advancing new therapies, including Idorsia Pharmaceuticals, Sanofi, Sangamo Therapeutics, UniQure Biopharma, and 4D Molecular Therapeutics. The global scope of Fabry disease research is further reinforced by active development programs across Asia, with Japanese, South Korean, and other regional sponsors contributing meaningfully to the clinical pipeline.
Key therapies currently on the market or under development include GALAFOLD (migalastat), ELFABRIO (pegunigalsidase alfa), FABRAZYME (agalsidase beta), REPLAGAL (agalsidase alfa), Lucerastat, Venglustat, ST-920, AMT-191, and 4D-310, among others. In March 2025, Sangamo Therapeutics reached an agreement with the FDA on an accelerated approval pathway for ST-920, with a Biologics License Application expected in the latter half of 2025. Sanofi indicated in January 2025 that regulatory submission for venglustat is planned for 2026, while Idorsia expects Phase III Open-label Extension study results in Q2 2025.
Discover which Fabry disease medications are expected to grab the market share @ Fabry Disease Market Report
Fabry disease is a rare, hereditary lysosomal storage disorder caused by mutations in the GLA gene, leading to a deficiency of the enzyme alpha-galactosidase A. Without adequate enzyme activity, the fatty compound globotriaosylceramide (Gb3 or GL-3) accumulates in the cells of blood vessels, nerves, and vital organs, causing progressive damage. Symptoms typically emerge in childhood and include burning pain in the extremities, skin lesions, reduced sweating, digestive issues, and eye abnormalities. Over time, the disease can lead to kidney failure, heart disease, and stroke. Diagnosis involves enzyme activity testing, genetic analysis, and organ imaging or biopsy. Early treatment with ERT or chaperone therapy is critical to slowing disease progression.
DelveInsight's report provides a thorough epidemiological analysis of the 7MM from 2020 to 2034, covering total diagnosed prevalence segmented by gender, age, and phenotype, and drawing on multiple studies and expert perspectives to illuminate the factors shaping patient population trends.
Download the report to understand which factors are driving Fabry disease epidemiology trends @ Fabry Disease Treatment Market
Fabry disease management centers on ERT, oral chaperone therapy, and supportive care including ACE inhibitors and analgesics. In the United States, three therapies are approved: ELFABRIO (Chiesi/Protalix), GALAFOLD (Amicus), and FABRAZYME (Sanofi-Genzyme).
Europe offers four approved options, while Japan provides REPLAGAL and GALAFOLD and is notable for having introduced agalsidase beta biosimilars. FABRAZYME, approved by the FDA in 2003 and available in over 70 countries, remains a cornerstone of ERT. Patent expiry in Japan has enabled biosimilars such as agalsidase beta BS (JR-051) from JCR Pharmaceuticals. REPLAGAL, approved in Europe and Japan but never in the U.S. following Shire's withdrawal of its FDA application in 2012, remains available in more than 35 countries. ELFABRIO, a pegylated ERT from Chiesi/Protalix, represents a further advancement in the ERT class. Despite clinical benefits, ERT carries ongoing challenges including frequent infusions, venous access difficulties, infection risks, pediatric complications, and the potential emergence of antidrug antibodies. GALAFOLD (migalastat), the first oral chaperone therapy approved by the FDA in 2018, targets specific GLA mutations and benefits an estimated 35–50% of patients by stabilizing the enzyme and reducing GL-3 accumulation.
Learn more about the Fabry disease treatment options @ Fabry Disease Drugs
The Fabry disease pipeline is active and geographically diverse. ST-920 (Sangamo Therapeutics) is a liver-targeting gene therapy delivered as a single intravenous infusion via a recombinant AAV 2/6 vector, designed to introduce a functional α-galactosidase A gene into liver cells for sustained, long-term enzyme production - a potential alternative to the ongoing infusion burden of traditional ERT. Venglustat (Sanofi) is an investigational oral substrate reduction therapy that inhibits glucosylceramide synthase (GCS) to reduce glycosphingolipid synthesis, including Gb3. In Japan, Sanofi K.K. is the registered local sponsor of the CARAT trial (jRCT2071220022), a Phase 3 randomized open-label study evaluating venglustat's impact on cardiac parameters such as left ventricular mass index in adult Fabry patients. As of early 2026, the trial showed reductions in biomarkers including lyso-GL-3 and some symptom improvements, but did not meet its primary efficacy endpoint, prompting further analysis and regulatory discussions.
South Korean company ISU ABXIS Co., Ltd. is advancing ISU303 (Fabagal®), a biosimilar of agalsidase beta that works as a recombinant ERT to degrade accumulated Gb3 in lysosomes. After completing a Phase 1 study in healthy volunteers and a Phase 2 trial in ten Korean Fabry patients - which showed significant reductions in plasma and urine Gb3 levels - ISU303 has progressed into an ongoing Phase 3 randomized, double-blind, active-controlled trial comparing Fabagal® against FABRAZYME (NCT06081062), with completion targeted around 2026. If successful, ISU303 could offer a cost-competitive biosimilar alternative in markets where branded ERT access remains limited. Taiwan, while not yet home to a sponsored Phase 1–3 Fabry disease trial, participates as a trial site in international studies, and academic groups there are pursuing early-stage research into novel oral agents targeting RNA mis-splicing in cardiac Fabry disease, representing potential future pipeline activity.
The anticipated launch of these emerging therapies - spanning gene therapy, oral substrate reduction, and biosimilar ERT - is expected to transform treatment standards and unlock new commercial opportunities across the 7MM.
To know more about Fabry disease clinical trials, visit @ Fabry Disease Pipeline Market
The Fabry disease market outlook through 2034 is shaped by both significant opportunities and persistent challenges. Expanded newborn screening and improved genetic testing are enabling earlier diagnoses and treatment initiation, positively impacting patient outcomes. A broadening range of therapeutic modalities - from gene therapy to biosimilars - is diversifying the treatment landscape. However, the highly variable nature of disease presentation complicates diagnosis and standardization of care. Mutation-specific therapies like GALAFOLD limit eligibility to a subset of patients. High treatment costs create access barriers, particularly in resource-limited settings. Additional risks include pipeline failures, pricing and reimbursement obstacles, specialist shortages, and persistent underdiagnosis. Taken together, the convergence of a growing patient population, a geographically diversified pipeline, and transformative therapeutic innovation positions the Fabry disease market for sustained and meaningful growth through 2034.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Related report
Fabry Disease Epidemiology Forecast - 2034
DelveInsight’s “Fabry Disease – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Fabry disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. The leading Fabry Disease Companies developing therapies include Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma and others.
Fabry Disease Pipeline Insight, 2026
DelveInsight’s, “Fabry Disease Pipeline Insight, 2026,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Fabry Disease pipeline landscape. The leading Fabry Disease Companies developing therapies include Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma and others.
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com